An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Cottonwood
- Sponsors Roche
- 28 Jun 2019 Baseline time point changed from 7 years to 9 years according to clinicaltrial.gov record.
- 28 Jun 2019 Planned number of patients changed from 2625 to 2100.
- 28 Jun 2019 Planned End Date changed from 8 Apr 2025 to 16 Aug 2025.